BlackRock Inc. Takes $6.74 Million Position in Artiva Biotherapeutics, Inc. $ARTV

BlackRock Inc. purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 694,726 shares of the company's stock, valued at approximately $6,739,000. BlackRock Inc. owned 2.81% of Artiva Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Citadel Advisors LLC boosted its position in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock worth $2,291,000 after purchasing an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after buying an additional 117,733 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics during the fourth quarter worth approximately $341,000. Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $67,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $112,000.

Artiva Biotherapeutics Trading Up 0.5%

NASDAQ ARTV opened at $11.19 on Friday. The stock's fifty day moving average price is $10.57 and its 200-day moving average price is $8.75. The stock has a market cap of $547.08 million, a P/E ratio of -3.39 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ARTV. Cantor Fitzgerald reissued an "overweight" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, May 8th. Wedbush upped their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a report on Monday, May 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.

Insider Buying and Selling at Artiva Biotherapeutics

In related news, insider Subhashis Banerjee sold 8,222 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the sale, the insider directly owned 142,047 shares of the company's stock, valued at $1,705,984.47. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 24,944 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the acquisition, the director directly owned 17,329,570 shares of the company's stock, valued at $172,082,630.10. The trade was a 0.14% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 1,965,251 shares of company stock worth $16,188,035. Company insiders own 1.80% of the company's stock.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

Want to see what other hedge funds are holding ARTV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source